AAAAI MEETING: Sanofi, Regeneron's dupilumab shows rapid effect in atopic dermatitis
This article was originally published in Scrip
Executive Summary
Dupilumab from Sanofi and Regeneron Pharmaceuticals showed a rapid and statistically significant effect on moderate-to-severe atopic dermatitis (AD) in Phase IIa data from a European clinical trial that were presented on 4 March in an oral late-breaker session at the American Academy of Allergy, Asthma and Immunology (AAAAI) annual meeting in San Diego.